Vertex Pharmaceuticals

NASDAQ: VRTX
$263.82
-$3.76 (-1.4%)
Closing price September 23, 2020
Tuesday's top analyst upgrades, downgrades and initiations included Albermarle, Amgen, Applied Materials, Biogen, CRISPR Therapeutics, CrowdStrike, CSX, Kroger, Slack, Teva Pharmaceutical and Xerox.
Tuesday's the top analyst upgrades, downgrades and initiations included Dropbox, Electronic Arts, Halliburton, Intuit, Juniper Networks, ProLogis, Silicon Motion, Taiwan Semiconductor, Textron and...
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Friday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Alphabet, Altria, Amazon.com, Boeing, Caterpillar, Chipotle Mexican Grill, E*Trade, Gap, Snap and Twitter.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, CSX, IBM, Netflix, Occidental Petroleum, Whiting Petroleum, Amgen, Gilead Sciences, Merck and Pfizer.
These four stocks make good sense now, as they all have outstanding upside potential and are among the Jefferies top U.S. growth calls for this week.
On top of the company announcing an acquisition on Tuesday, Vertex has seen a substantial analyst upgrade from Goldman Sachs.
Here are three biotech stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross, plus two that went the other way.
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some of these analyst reports cover stocks to buy, while others cover...
CRISPR Therapeutics shares jumped on Tuesday after the firm announced that the FDA has granted Fast Track Designation for its treatment for transfusion-dependent beta thalassemia.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex Pharmaceuticals and Voya Financial.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen, Southern Copper, Vertex Pharmaceuticals and...
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Aflac, Akamai, BioMarin, Caesars Entertainment, CBS, Crocs, GW Pharma, Medtronic, Netflix and Sirius XM.